Search Results - "Piech, CT"

Daily cost of an intensive care unit day: The contribution of mechanical ventilation by Dasta, Joseph F, McLaughlin, Trent P, Mody, Samir H, Piech, Catherine Tak

“…OBJECTIVE:To quantify the mean daily cost of intensive care, identify key factors associated with increased cost, and determine the incremental cost of…”
Get full text

PMS32 ANTI-TUMOR NECROSIS FACTOR SWITCHING, DISCONTINUATION, AND PERSISTENCE IN MANAGED CARE PATIENTS WITH RHEUMATOID ARTHRITIS by Buysman, E, Tang, B, Carter, C, Piech, CT

Get full text

PMS68 DOSES AND INFUSION INTERVALS FOR INFLIXIMAB IN ANTI-TNF NAiVE AND ANTI-TNF EXPERIENCED MANAGED CARE PATIENTS WITH RHEUMATOID ARTHRITIS by Carter, C, Tang, B, Changolkar, A, McKenzie, RS, Piech, CT

Get full text

PMS7 COST ANALYSIS OF RECENTLY APPROVED AND OLDER ANTI-TNF BIOLOGIC AGENTS USED IN RHEUMATOID ARTHRITIS by Carter, C, Schmeichel-Mueller, C, McKenzie, RS, Piech, CT

Get full text

PMS56 PHARMACY REFILL PATTERNS FOR SUBCUTANEOUS ANTI-TUMOR NECROSIS FACTOR AGENTS USED IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN A MANAGED CARE SETTING by Carter, C, Tang, B, Changolkar, A, McKenzie, RS, Piech, CT

Get full text

PSY7 DISEASE FLARES AMONG PATIENTS WITH CROHN'S DISEASE by Waters, HC, Bolge, SC, Freedman, D, Piech, CT

Get full text

PMS8 BIOLOGIC THERAPY REDUCES PATIENT-REPORTED SEVERITY OF RHEUMATOID ARTHRITIS IN THE REAL WORLD SETTING by Tang, B, McKenzie, RS, Freedman, D, Wagner, S, Piech, CT

Get full text

PSY47 CROHN'S DISEASE TREATMENT PARADIGM by Waters, HC, Bolge, SC, Freedman, D, Piech, CT

Get full text

PMS7 A 2-YEAR EVALUATION OF INFLIXIMAB'S EFFECTIVENESS IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ACTUAL PRACTICE by Tang, B, Rahman, M, Naim, A, Meissner, B, Dehoratius, R, Piech, CT

Get full text

PMS32 HIGHER OUT-OF-POCKET PHARMACY EXPENSE IS ASSOCIATED WITH HIGHER SWITCHING RATES AMONG ANTI-TUMOR NECROSIS FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS by Tang, B, Changolkar, A, McKenzie, RS, Piech, CT

Get full text

MS3 THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS by Tang, B, McKenzie, RS, Freedman, D, Wagner, S, Piech, CT

Get full text

PCN7 CLINICAL AND ECONOMIC OUTCOMES IN CANCER CHEMOTHERAPY PATIENTS INITIATED ON ERYTHROPOIESIS STIMULATING AGENTS (ESA) AT HEMOGLOBIN (HB) LEVELS < 10 G/DL by Burton, T, Larholt, K, Apgar, E, Pashos, CL, McKenzie, RS, Piech, CT

Get full text

PMS39 IMPAIRMENTS IN QUALITY OF LIFE, DAILY FUNCTION, AND WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES by Tang, B, Naim, A, McKenzie, RS, Bailey, R, Freedman, D, Wagner, S, Piech, CT

Get full text

CN1 RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING by Lafeuille, MH, Bailey, R, Vekeman, F, Piech, CT, McKenzie, RS, Lefebvre, P

Get full text

PCN18 CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY by Nuyts, G, Janagap, C, Zilberberg, M, Piech, CT

Get full text

PG111 A COST-EFFICACY ANALYSIS MODEL FOR PHYSICIAN ADMINISTERED ANTI-TUMOR NECROSIS FACTOR AGENTS IN CROHN'S DISEASE by Waters, H, McKenzie, RS, Tang, B, Piech, CT, Papandrikopoulou, N

Get full text

PG117 REALWORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHN'S DISEASE by Waters, H, Meekins, T, Bewtra, A, McKenzie, RS, Tang, B, Piech, CT, Papandrikopoulou, N

Get full text

PUK10 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS by Mody, S, Padmanabhan, V, McKenzie, S, Piech, CT

Get full text

Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve by Duh, Mei Sheng, Lefebvre, Patrick, Fastenau, John, Piech, Catherine Tak, Waltzman, Roger J.

“…Introduction. In assessing erythropoietic agents for chemotherapy‐induced anemia, traditional single time–point end points (e.g., hematopoietic response [HR])…”
Get full text

Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents by Mark, Tami L., Scott McKenzie, R., Fastenau, John, Piech, Catherine Tak

“…ABSTRACT Objective: Epoetin alfa (EPO) and darbepoetin alfa (DARB) are approved for the treatment of chemotherapy-related anemia (CRA) in patients with…”
Get full text